Frequently Asked Questions About 2526.HK

How is 2526.HK valued?

Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK)'s valuation is shown across multiple multiples on this page — P/E, P/B, P/S, EV/EBITDA, P/FCF — with both current and historical context. When trailing earnings are negative, forward-looking multiples and revenue / cash-flow ratios become more relevant.

Is 2526.HK undervalued or overvalued?

Hangzhou Diagens Biotechnology Co., Ltd.'s current valuation multiples are compared against the stock's own historical range and against sector peers on this page. A multiple in the lowest percentile of its 10-year history is typically considered undervalued (with caveats — the analyst price target card adds another data point).

What is the analyst price target for 2526.HK?

The Wall Street price-target card on this page shows the consensus 12-month price target for Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK), the high and low range, and the implied upside or downside vs the current share price. Individual analyst ratings are listed below the target range.

What is 2526.HK's EV/EBITDA?

Hangzhou Diagens Biotechnology Co., Ltd.'s enterprise-value-to-EBITDA multiple is shown on this page. EV/EBITDA is capital-structure neutral (unlike P/E) and is especially useful for comparing companies with different debt levels — a common screen for value investors.

2526.HK (Hangzhou Diagens Biotechnology Co., Ltd.) is a recent IPO.

It began trading on March 29, 2026, giving it under six months of public history. Many charts and metrics below are sparse or empty until more price, financial, and analyst history accumulates — the affected sections are flagged individually so you can tell limited history from missing data.

2526.HK

Hangzhou Diagens Biotechnology Co., Ltd.

HKSE·Medical, Devices · Healthcare

HK$299.60HK$7.80−2.54%

Market capHK$26.63B·Market closed·Jul 22 3:58 AM UTC

P/E Ratio

Current—

Daily data isn’t available yet — 2526.HK IPO’d March 29, 2026, so there isn’t enough history for this view. It will fill in as trading and filing history accumulate.

Chart tools

Open P/E Ratio in Chart Builder to fine-tune colors, labels, and timeframe, then download a high-res PNG.

Y-axis

Export Chart

P/B Ratio

Current—

Daily data isn’t available yet — 2526.HK IPO’d March 29, 2026, so there isn’t enough history for this view. It will fill in as trading and filing history accumulate.

Chart tools

Open P/B Ratio in Chart Builder to fine-tune colors, labels, and timeframe, then download a high-res PNG.

Y-axis

Export Chart

P/S Ratio

Current—

Daily data isn’t available yet — 2526.HK IPO’d March 29, 2026, so there isn’t enough history for this view. It will fill in as trading and filing history accumulate.

Chart tools

Open P/S Ratio in Chart Builder to fine-tune colors, labels, and timeframe, then download a high-res PNG.

Y-axis

Export Chart

P/OCF Ratio

Current—

Daily data isn’t available yet — 2526.HK IPO’d March 29, 2026, so there isn’t enough history for this view. It will fill in as trading and filing history accumulate.

Chart tools

Open P/OCF Ratio in Chart Builder to fine-tune colors, labels, and timeframe, then download a high-res PNG.

Y-axis

Export Chart

P/FCF Ratio

Current—

Daily data isn’t available yet — 2526.HK IPO’d March 29, 2026, so there isn’t enough history for this view. It will fill in as trading and filing history accumulate.

Chart tools

Open P/FCF Ratio in Chart Builder to fine-tune colors, labels, and timeframe, then download a high-res PNG.

Y-axis

Export Chart

PEG Ratio

Current—

Daily data isn’t available yet — 2526.HK IPO’d March 29, 2026, so there isn’t enough history for this view. It will fill in as trading and filing history accumulate.

Chart tools

Open PEG Ratio in Chart Builder to fine-tune colors, labels, and timeframe, then download a high-res PNG.

Y-axis

Export Chart

EV/EBITDA

Current—

This data isn’t available yet — 2526.HK IPO’d March 29, 2026, so there isn’t enough history for this view. It will fill in as trading and filing history accumulate.

Chart tools

Open EV/EBITDA in Chart Builder to fine-tune colors, labels, and timeframe, then download a high-res PNG.

Y-axis

Export Chart

Frequently Asked Questions About 2526.HK

How is 2526.HK valued?: Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK)'s valuation is shown across multiple multiples on this page — P/E, P/B, P/S, EV/EBITDA, P/FCF — with both current and historical context. When trailing earnings are negative, forward-looking multiples and revenue / cash-flow ratios become more relevant.
Is 2526.HK undervalued or overvalued?: Hangzhou Diagens Biotechnology Co., Ltd.'s current valuation multiples are compared against the stock's own historical range and against sector peers on this page. A multiple in the lowest percentile of its 10-year history is typically considered undervalued (with caveats — the analyst price target card adds another data point).
What is the analyst price target for 2526.HK?: The Wall Street price-target card on this page shows the consensus 12-month price target for Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK), the high and low range, and the implied upside or downside vs the current share price. Individual analyst ratings are listed below the target range.
What is 2526.HK's EV/EBITDA?: Hangzhou Diagens Biotechnology Co., Ltd.'s enterprise-value-to-EBITDA multiple is shown on this page. EV/EBITDA is capital-structure neutral (unlike P/E) and is especially useful for comparing companies with different debt levels — a common screen for value investors.

Hangzhou Diagens Biotechnology Co., Ltd.

Frequently Asked Questions About 2526.HK

Hangzhou Diagens Biotechnology Co., Ltd.

P/E Ratio

P/B Ratio

P/S Ratio

P/OCF Ratio

P/FCF Ratio

PEG Ratio

EV/EBITDA

Frequently Asked Questions About 2526.HK

P/E Ratio

P/E Analyzer

P/B Ratio

P/S Ratio

P/OCF Ratio

P/FCF Ratio

PEG Ratio

EV/EBITDA

P/E Analyzer